GlassScriptPhysician profile
Ushasri Challa
NPI 1992756563
$2,741.96
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $573 · 2020: $49.86 · 2021: $32.25 · 2022: $543 · 2023: $817 · 2024: $727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,444 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,444.31 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $294.78 | 2019-2024 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $277.01 | 2022-2024 | Acthar, Terlivaz |
| Astrazeneca Pharmaceuticals LP | $272.39 | 2019-2024 | Farxiga, Lokelma, Flumist Quadrivalent |
| Calliditas Therapeutics US INC. | $199.36 | 2022-2024 | Tarpeyo |
| Vifor Pharma, INC. | $191.45 | 2019-2024 | Veltassa |
| Amgen INC. | $172.77 | 2019-2024 | Tavneos, Krystexxa |
| Aurinia Pharma U.S., INC. | $160.23 | 2022-2024 | Lupkynis |
| Mallinckrodt Enterprises LLC | $154.54 | 2019 | |
| Novartis Pharmaceuticals Corporation | $118.19 | 2023-2024 | |
| Akebia Therapeutics INC | $93.80 | 2019-2022 | |
| Fresenius USA Marketing, INC. | $90.10 | 2019-2024 | Liberty Select Cycler, Nxstage System One |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.74 | 2023-2024 | Jardiance |
| Shire North American Group INC | $70.08 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $66.47 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.38 | 2021-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $47.84 | 2022 | |
| Novo Nordisk INC | $47.78 | 2023-2024 | Ozempic, Rybelsus |
| Xeris Pharmaceuticals, INC. | $44.46 | 2024 | Keveyis |
| Ardelyx, INC. | $40.56 | 2024 | Ibsrela |
| Horizon Therapeutics Plc | $39.23 | 2023 | Krystexxa |
| Glaxosmithkline, LLC. | $38.47 | 2019-2023 | Benlysta |
| Alexion Pharmaceuticals, INC. | $33.71 | 2022-2023 | Ultomiris |
| Travere Therapeutics, INC. | $31.07 | 2019-2020 | |
| Genzyme Corporation | $26.23 | 2024 | |
| Kyowa Kirin, INC. | $23.98 | 2023 | Crysvita |
| Alnylam Pharmaceuticals INC. | $18.26 | 2023 | Oxlumo |
| Nxstage Medical, INC. | $16.81 | 2019 | |
| Daiichi Sankyo INC. | $15.29 | 2022 | |
| Genentech USA, INC. | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ushasri Challa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.